Latest News
-
-
AGC Biologics collaborates with ATUM to accelerate drug development via advanced cell line technology
AGC Biologics now offers the ATUM transposase-based platform as part of its growing portfolio of cell line development solutions.
-
MIT Jameel Clinic collaborates with Japan to test Cancer prediction AI Mirai
The partnership will begin with a study focused on assessing Mirai’s ability to predict breast cancer risk specifically in Japanese women using mammography images.
-
Takeda-Innovent closes USD11.4B immuno-oncology partnership
The two pharmaceutical giants originally signed the agreement in October 2025, establishing a framework centered on bispecific antibodies and ADCs.
-
Aster DM Healthcare dominates Newsweek’s Specialized Hospital List
Currently operating 15 hospitals across the GCC, Aster DM Healthcare continues to drive healthcare excellence by expanding centers of excellence, incorporating advanced diagnostic technologies, and implementing best-practice medical protocols within its network.
-
Roche receives FDA clearance for rapid 15-minute pertussis PCR test
The test distinguishes between three distinct Bordetella species that cause different types of illness: B. pertussis, B. parapertussis and B. holmesii
-
Dis-Chem Founder Ivan Saltzman to step down as executive director in June 2026
Saltzman, 75, co-founded Dis-Chem with his wife, Lynette, in 1978 and has played a central role in transforming the business from a family-run operation into a national chain.
-
The Herbal Divide: Why Asia embraces traditional medicine, while the West holds back
Herbal medicine is extremely popular among the Chinese public for both prevention and treatment, but unlike many Western countries, China has policies designed to address a growing disease burden among an aging population and wholeheartedly supports the use of herbal medicines.
-
Morocco pledges USD5M to Gavi, becoming the major North African donor
Morocco’s pledge is timely, as Gavi prepares to implement its next strategic phase, known as “Gavi 6.0,” which aims to protect 500 million children between 2026 and 2030
-
ZAMRA approves lenacapavir for HIV prevention in record time
The Zambia Medicines Regulatory Authority (ZAMRA) granted approval on November 4, 2025, completing its review in just 12 working days through an innovative regulatory pathway.